Tilsotolimod

Modify Date: 2025-08-26 01:19:08

Use of Tilsotolimod

Tilsotolimod is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models.

Name	Tilsotolimod

Description	Tilsotolimod is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models.
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Toll-like Receptor (TLR) Research Areas >> Cancer
References	[1]. Karime C, Wang J, Woodhead G, et al. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opin Investig Drugs. 2022;31(1):1-13. [2]. Haymaker C, Johnson DH, Murthy R, et al. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. Cancer Discov. 2021;11(8):1996-2013. [3]. Babiker H, Borazanci E, Subbiah V, et al. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res. 2022;28(23):5079-5087.

Description

Tilsotolimod is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models.

Related Catalog

Signaling Pathways >> Immunology/Inflammation >> Toll-like Receptor (TLR)

Research Areas >> Cancer

References

Molecular Formula	C₂₂₃H₂₈₄N₇₄O₁₁₅P₂₂S₂₂
Molecular Weight	7228.00